Airsupra Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Inhalation aerosol—10.7g (120 inh)
Manufacturer
Generic Availability
NO
Mechanism of Action
Albuterol is a beta2-adrenergic agonist. The pharmacologic effects of albuterol sulfate are attributable to activation of beta2-adrenergic receptors on airway smooth muscle. Activation of beta2-adrenergic receptors leads to the activation of adenylcyclase and to an increase in the intracellular concentration of cyclic-3', 5'-adenosine monophosphate (cAMP). This increase of cAMP is associated with the activation of protein kinase A, which in turn inhibits the phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in muscle relaxation. Albuterol relaxes the smooth muscle of all airways, from the trachea to the terminal bronchioles.
Budesonide is an anti-inflammatory corticosteroid that exhibits potent glucocorticoid activity and weak mineralocorticoid activity. Inflammation is an important component in the pathogenesis of asthma. Corticosteroids have a wide range of inhibitory activities against multiple cell types (eg, mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (eg, histamine, eicosanoids, leukotrienes, and cytokines) involved in allergic and non-allergic-mediated inflammation. These anti-inflammatory actions of corticosteroids may contribute to their efficacy in asthma.
Airsupra Indications
Indications
As-needed or prophylactic therapy of bronchoconstriction and to reduce risk of exacerbations in adults with asthma.
Airsupra Dosage and Administration
Adult
≥18yrs: 2 inh as needed for symptoms; max 12 inh/day. Rinse mouth after use.
Children
<18yrs: not established.
Airsupra Contraindications
Not Applicable
Airsupra Boxed Warnings
Not Applicable
Airsupra Warnings/Precautions
Warnings/Precautions
Do not exceed recommended dose. Evaluate if deterioration of asthma (eg, if symptoms continue or more doses required). Discontinue if hypersensitivity reactions or paradoxical bronchospasm (use alternative therapy) occurs. Cardiovascular disorders (eg, coronary insufficiency, cardiac arrhythmias, hypertension). Convulsive disorders. Hyperthyroidism. Diabetes. Hyperresponsiveness to sympathomimetics. Hypokalemia. Immunosuppressed. Tuberculosis. Systemic infections. Ocular herpes simplex. If exposed to chickenpox or measles, consider immune globulin prophylaxis or antiviral treatment. Post-op or during stress: monitor adrenal response. Monitor for hypercorticism and HPA axis suppression. Assess bone mineral density if risk factors exist (eg, prolonged immobilization, osteoporosis, postmenopausal, tobacco use, advanced age, poor nutrition, chronic use of drugs that can reduce bone mass [eg, anticonvulsants, oral corticosteroids]). Hepatic impairment; monitor. Elderly. Labor & delivery. Pregnancy. Nursing mothers.
Airsupra Pharmacokinetics
Distribution
Albuterol:
- Mean apparent volume of distribution (Vz/F): 565.7 L.
Budesonide:
- Mean apparent volume of distribution (Vz/F): 1002 L.
- Plasma protein bound: 85–90%.
Elimination
Albuterol:
- renal.
- Half-life: ~7.1 hours.
Budesonide:
- renal, fecal.
- Half-life: ~4.1 hours.
Airsupra Interactions
Interactions
Caution with concomitant strong CYP3A4 inhibitors (eg, ketoconazole, ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin), during or within 2 weeks of discontinuing MAOIs or tricyclic antidepressants, β-blockers (consider cardioselective), K+-depleting diuretics, other short-acting beta-agonists. Concomitant digoxin: monitor serum levels.
Airsupra Adverse Reactions
Adverse Reactions
Headache, oral candidiasis, cough, dysphonia; paradoxical bronchospasm, cardiovascular effects, hypersensitivity reactions, infections, decreased bone mineral density, glaucoma, increased IOP, cataracts.
Airsupra Clinical Trials
See Literature
Airsupra Note
Not Applicable
Airsupra Patient Counseling
See Literature
Images
